None of the commercial brands tested for mBDNF quantification showed optimal specificity, although R&D Systems (#DBD00) showed an acceptable result
Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing
BPC-157 works by supporting these natural processes that are already happening in your body
K., Brzezik, J., Madra-Gackowska, K., & Szeleszczuk, L
In the UK, hydroxocobalamin is the standard form used for intramuscular injections on the NHS